Article Text

Download PDFPDF

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
  1. Gordon John Sampson Rustin, MD, MSc, FRCP*,
  2. Ignace Vergote, MD, PhD,
  3. Elizabeth Eisenhauer, MD,
  4. Eric Pujade-Lauraine, MD§,
  5. Michael Quinn, MBBCh, MSc, MRCP,
  6. Tate Thigpen, MD,
  7. Andreas du Bois, MD, PhD**,
  8. Gunnar Kristensen, MD, PhD,,
  9. Anders Jakobsen, MD,,
  10. Satoru Sagae, MD, PhD§§,
  11. Kathryn Greven, MD∥∥,
  12. Mahesh Parmar, MD¶¶,
  13. Michael Friedlander, MD, PhD***,
  14. Andres Cervantes, MD, PhD††† and
  15. Jan Vermorken, MD, PhD‡‡‡
  1. * Mount Vernon Hospital, Northwood, UK;
  2. University Hospital Leuven, Leuven, Belgium;
  3. NCIC Clinical Trials Group, Kingston, Ontario, Canada;
  4. § Hopital Hotel Dieu, Paris, France;
  5. Royal Women's Hospital, Melbourne, Australia;
  6. University of Mississippi School of Medicine, Jackson, MS;
  7. ** Dr Horst-Schmidt-Klinik, Wiesbaden, Germany;
  8. †† Norwegian Radium Hospital, Oslo, Norway;
  9. ‡‡ Vejle Hospital, Vejle, Denmark;
  10. §§ Sapporo Railway Hospital, Sapporo, Japan;
  11. ∥∥ Wake Forest University Medical Center, Winston Salem, NC;
  12. ¶¶ MRC Clinical Trials Unit, London, UK;
  13. *** Prince of Wales Cancer Centre, Randwick, NSW, Australia;
  14. ††† Hospital Clínico, University of Valencia, Valencia, Spain;
  15. ‡‡‡ Antwerp University Hospital, Edegem, Belgium.
  1. Address correspondence and reprint requests to Gordon John Sampson Rustin, MD, MSc, FRCP, Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex HA62RN, UK. E-mail: grustin{at}


The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well as the criteria to define response to treatment in recurrent disease using the serum marker CA 125 and has specified the situations where these criteria should be used. However, the publications did not include detailed definitions, nor were they written to accommodate the new version of Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1) now available. Thus, we recommend that the definitions described later in detail are incorporated into clinical trial protocols to maintain consistency. The criteria for defining progression are now acceptable in clinical trials of recurrent disease as they have since been validated (Pujade-Lauraine, personal communication, 2010). The GCIG requests that data from all clinical trials using these definitions are made available to GCIG trial centers so that continual validation and improvement can be accomplished. These definitions were developed from analyzing patients receiving cytotoxic chemotherapy and have not yet been validated in patients receiving molecular targeting agents.

  • CA 125
  • Ovarian cancer
  • Response
  • Progression
  • Clinical trials

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.